News & Events
The BBB Program conducts an internationally acclaimed annual meeting of leading clinical and preclinical experts in brain tumors and the blood-brain barrier. The 23rd annual meeting will be held March 2-4, 2017 at Skamania Lodge, Stevenson, Washington, in collaboration with the International Brain Barriers Society.
A $5 million grant from the Walter S. and Lucienne Driskill Foundation will advance OHSU's efforts to develop new, nonsurgical treatments for malignant brain tumors and to share its unique knowledge with the international medical community. The Chicago based Driskill Foundation's grant supports OHSU's Neuro-Oncology and Blood-Brain Barrier Program, led by neuro-oncologist Edward A. Neuwelt, M.D. Read more
Recent Scientific Publications
For a list of selected publications from Dr. Neuwelt and the BBB Program, please see the Publications page.
Muldoon LL, Gahramanov S, Li X, Marshall DJ, Kraemer DF, Neuwelt EA. Dynamic magnetic resonance imaging assessment of vascular targeting agent effects in rat intracerebral tumor models. Neuro Oncol 13(1): 51-60, 2011.
We used serial dynamic contrast enhanced MRI at 12 Tesla to evaluate the effects of monoclonal antibodies targeting brain tumor vasculature: α(V)-integrins (intetumumab; CNTO 95) vs vascular endothelial growth factor (bevacizumab; Avastin) in rats with intracerebral tumor model. Intetumumab and bevacizumab had diametrically opposite effects on rat brain tumor vasculature: Targeting α(V)-integrins increased tumor vascular permeability and blood volume, whereas bevacizumab decreased both measures. These findings have implications for chemotherapy delivery and antitumor efficacy.
Gahramanov S, Muldoon LL, Li X, Neuwelt EA. Improved perfusion MRI using ferumoxytol of intracerebral tumor blood volume and antiangiogenic therapy efficacy in a rat model. Radiology. 2011 Dec;261(3):796-804. Epub 2011 Sep 21. PMID: 2194050
This rodent study confirms underestimation of brain tumor relative cerebral blood volume (rCBV) measurements using low-molecular-weight gadolinium-based contrast agents, due to extravasation artifacts. Our findings suggest that using ferumoxytol iron oxide nanoparticles for perfusion MRI provides more consistent rCBV estimation regardless of permeability of the tumor vasculature.
Brock PR, Knight KR, Freyer DR, Campbell KC, Steyger PS, Blakley BW, Rassekh SR, Chang KW, Fligor BJ, Rajput K, Sullivan M, Neuwelt EA. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new international society of pediatric oncology Boston ototoxicity scale. J Clin Oncol. 2012 Jul 1;30(19):2408-17. Epub 2012 Apr 30.
This review summarizes recommendations made at the 42nd Annual Meeting of the International Society of Pediatric Oncology (SIOP) 2010 in Boston regarding reducing cisplatin and high-dose carboplatin ototoxicity without reducing anti-tumor efficacy.
Wu YJ, Muldoon LL, Gahramanov S, Kraemer DF, Marshall DJ, Neuwelt EA. Targeting αv integrins decreased metastasis and increased survival in a nude rat breast cancer brain metastasis model. In press, J Neurooncology, 2012. PMID: 22842979, Epub ahead of print
Intetumumab monoclonal antibody targeting α(V)-integrin cell-cell adhesion proteins reduced the incidence of breast cancer brain metastases in a rat model of hematogenous metastases. Giving intetumumab either before or up to one week after tumor cell infusion decreased the number of brain metastases, delayed their appearance on MRI, and improved rat survival.